The absence of a single immune cell receptor has been linked to both fewer defenses against mycobacterial infections, such as TB, and damaging buildup of sticky residue in the lungs.
A class of ineffective immune cells may be driving Alzheimer’s disease, a finding that could both explain why APOE4 gene increases the risk of the disease and why a new drug can impact it.
Luciano Marraffini’s research helped lay the groundwork for the newly FDA-approved CRISPR-based therapy for sickle cell anemia. He reflects on how we got here—and where the science is going next.